A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high‐risk neuroblastoma

Neuroblastoma is a sympathetic nervous system tumor, primarily presenting in children under 6 years of age. The long‐term prognosis for patients with high‐risk neuroblastoma (HRNB) remains poor despite aggressive multimodal therapy. This report provides an update to a phase II trial evaluating DFMO...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Cancer
Main Authors: Lewis, Elizabeth C., Kraveka, Jacqueline M., Ferguson, William, Eslin, Don, Brown, Valerie I., Bergendahl, Genevieve, Roberts, William, Wada, Randal K., Oesterheld, Javier, Mitchell, Deanna, Foley, Jessica, Zage, Peter, Rawwas, Jawhar, Rich, Maria, Lorenzi, Elizabeth, Broglio, Kristine, Berry, Donald, Saulnier Sholler, Giselle L.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2020
Assuntos:
Cancer Therapy and Prevention
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7586843/
https://ncbi.nlm.nih.gov/pubmed/32391579
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.33044
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados